Wellington Management Group
ZVRA icon

Wellington Management Group’s Zevra Therapeutics ZVRA Stock Holding History

Wellington Management Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
164,538
+8,121
+5% +$90.3K ﹤0.01% 1595
2026
Q1 		$1.46M Sell
156,417
-13,892
-8% -$125K ﹤0.01% 1607
2025
Q4 		$1.53M Sell
170,309
-16,957
-9% -$160K ﹤0.01% 1652
2025
Q3 		$1.78M Buy
187,266
+40,982
+28% +$411K ﹤0.01% 1662
2025
Q2 		$1.29M Buy
146,284
+5,866
+4% +$47.6K ﹤0.01% 1678
2025
Q1 		$1.05M Buy
+140,418
New +$1.12M ﹤0.01% 1696
2024
Q2 		– Sell
-129,189
Closed -$749K – 1987
2024
Q1 		$749K Buy
+129,189
New +$794K ﹤0.01% 1744
2016
Q2 		– Sell
-3,931
Closed -$912K – 2194
2016
Q1 		$912K Sell
3,931
-5,612
-59% -$1.36M ﹤0.01% 1835
2015
Q4 		$3.03M Sell
9,543
-429
-4% -$116K ﹤0.01% 1510
2015
Q3 		$3.09M Sell
9,972
-5,702
-36% -$1.75M ﹤0.01% 1493
2015
Q2 		$4.61M Buy
+15,674
New +$3.42M ﹤0.01% 1426

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wellington Management Group's ZVRA Position: Q2 2026 in Review

Wellington Management Group increased its Zevra Therapeutics (ZVRA) stake by 5.2% in Q2 2026, buying an estimated $90.3K and bringing the position to 164,538 shares worth $2.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1595.

Wellington Management Group first reported a position in ZVRA in Q2 2015 and has held it in 11 quarters since. The position peaked at $4.61M in Q2 2015. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Wellington Management Group held 164,538 shares of Zevra Therapeutics worth $2.36M as of Q2 2026.
  • Wellington Management Group bought 8,121 Zevra Therapeutics shares in Q2 2026, an estimated $90.3K.
  • Zevra Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1595 holding.
  • Wellington Management Group first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 11 quarters since.
  • Wellington Management Group's Zevra Therapeutics position peaked at $4.61M in Q2 2015.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.